<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928628</url>
  </required_header>
  <id_info>
    <org_study_id>LG-ZVCL005</org_study_id>
    <nct_id>NCT01928628</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients</brief_title>
  <official_title>A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare and assess the efficacy and the safety of the combination agent of
      Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with essential
      hypertension
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean sitDBP from week 0 to week 40</measure>
    <time_frame>40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate at week 4 and 8</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Proportion (%) of patients with mean sitDBP&lt;90mmHg or proportion (%) of patients with mean reduction of sitDBP ≥10mmHg from week 0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Lercanidipine 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine10mg /Valsartan 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lercanidipine 10mg /Valsartan 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine 10mg</intervention_name>
    <arm_group_label>Lercanidipine 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine10mg /Valsartan 80mg</intervention_name>
    <arm_group_label>Lercanidipine10mg /Valsartan 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine 10mg /Valsartan 160mg</intervention_name>
    <arm_group_label>Lercanidipine 10mg /Valsartan 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipin 10mg Placebo</intervention_name>
    <arm_group_label>Lercanidipine10mg /Valsartan 80mg</arm_group_label>
    <arm_group_label>Lercanidipine 10mg /Valsartan 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine10mg /Valsartan 80mg Placebo</intervention_name>
    <arm_group_label>Lercanidipine 10mg</arm_group_label>
    <arm_group_label>Lercanidipine 10mg /Valsartan 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lercanidipine 10mg /Valsartan 160mg Placebo</intervention_name>
    <arm_group_label>Lercanidipine 10mg</arm_group_label>
    <arm_group_label>Lercanidipine10mg /Valsartan 80mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 20 to ≤75 years old

          -  Patient with essential hypertension

        Exclusion Criteria:

          -  When the BP level measured at screening was sitDBP&gt;120 mmHg or sitSBP &gt;180 mmHg

          -  Patient with difference in repeatedly measured blood pressures from the selected arm
             at screening was sitSBP≥ 20mmHg or sitDBP ≥ 10mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lercanidipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

